| Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10269), 99-111, 2021 | 5742 | 2021 |
| Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four … M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10277), 881-891, 2021 | 1421 | 2021 |
| The intersecting pandemics of tuberculosis and COVID-19: population-level and patient-level impact, clinical presentation, and corrective interventions K Dheda, T Perumal, H Moultrie, R Perumal, A Esmail, AJ Scott, ... The Lancet Respiratory Medicine 10 (6), 603-622, 2022 | 214 | 2022 |
| Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised … SA Madhi, AL Koen, A Izu, L Fairlie, CL Cutland, V Baillie, ... The Lancet HIV 8 (9), e568-e580, 2021 | 149 | 2021 |
| An all-oral 6-month regimen for multidrug-resistant tuberculosis: a multicenter, randomized controlled clinical trial (the NExT study) A Esmail, S Oelofse, C Lombard, R Perumal, L Mbuthini, ... American Journal of Respiratory and Critical Care Medicine 205 (10), 1214-1227, 2022 | 87 | 2022 |
| Post-COVID-19 condition 3 months after hospitalisation with SARS-CoV-2 in South Africa: a prospective cohort study M Dryden, C Mudara, C Vika, L Blumberg, N Mayet, C Cohen, S Tempia, ... The Lancet Global Health 10 (9), e1247-e1256, 2022 | 84 | 2022 |
| A cohort study of post-COVID-19 condition across the Beta, Delta, and Omicron waves in South Africa: 6-month follow-up of hospitalized and nonhospitalized participants W Jassat, C Mudara, C Vika, R Welch, T Arendse, M Dryden, L Blumberg, ... International Journal of Infectious Diseases 128, 102-111, 2023 | 60 | 2023 |
| Long COVID: a review and proposed visualization of the complexity of long COVID R Perumal, L Shunmugam, K Naidoo, SS Abdool Karim, D Wilkins, ... Frontiers in immunology 14, 1117464, 2023 | 59 | 2023 |
| Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A … SA Madhi, D Moodley, S Hanley, M Archary, Z Hoosain, U Lalloo, C Louw, ... The Lancet HIV 9 (5), e309-e322, 2022 | 51 | 2022 |
| The whole is greater than the sum of the parts: recognising missed opportunities for an optimal response to the rapidly maturing TB-HIV co-epidemic in South Africa R Perumal, N Padayatchi, E Stiefvater BMC public health 9, 1-7, 2009 | 49 | 2009 |
| Knowledge management as a strategic tool for human resource management at higher education institutions LN Govender, R Perumal, S Perumal South African Journal of Information Management 20 (1), 1-10, 2018 | 37 | 2018 |
| The changing paradigm of drug-resistant tuberculosis treatment: successes, pitfalls, and future perspectives N Dookie, SL Ngema, R Perumal, N Naicker, N Padayatchi, K Naidoo Clinical Microbiology Reviews 35 (4), e00180-19, 2022 | 36 | 2022 |
| Extrapulmonary tuberculosis in the setting of HIV hyperendemicity at a tertiary hospital in Durban, South Africa S Gounden, R Perumal, NP Magula Southern African Journal of Infectious Diseases 33 (3), 57-64, 2018 | 34 | 2018 |
| TB epidemiology: where are the young women? Know your tuberculosis epidemic, know your response R Perumal, K Naidoo, N Padayatchi BMC public health 18, 1-6, 2018 | 33 | 2018 |
| Rapid molecular assays for the diagnosis of drug-resistant tuberculosis L Nandlal, R Perumal, K Naidoo Infection and Drug Resistance, 4971-4984, 2022 | 27 | 2022 |
| A systematic review and meta-analysis of first-line tuberculosis drug concentrations and treatment outcomes R Perumal, K Naidoo, A Naidoo, G Ramachandran, A Requena-Mendez, ... The International Journal of Tuberculosis and Lung Disease 24 (1), 48-64, 2020 | 25 | 2020 |
| A moxifloxacin-based regimen for the treatment of recurrent, drug-sensitive pulmonary tuberculosis: an open-label, randomized, controlled trial R Perumal, N Padayatchi, N Yende-Zuma, A Naidoo, D Govender, ... Clinical Infectious Diseases 70 (1), 90-98, 2020 | 23 | 2020 |
| KN95 filtering facepiece respirators distributed in South Africa fail safety testing protocols L Mottay, J Le Roux, R Perumal, A Esmail, L Timm, S Sivarasu, K Dhea South African medical journal 111 (3), 234-239, 2021 | 22 | 2021 |
| Understanding the profile of tuberculosis and human immunodeficiency virus coinfection: insights from expanded HIV surveillance at a tuberculosis Facility in Durban, South Africa R Perumal, N Padayatchi, K Naidoo, S Knight International Scholarly Research Notices 2014 (1), 260329, 2014 | 16 | 2014 |
| Advances in tuberculosis control during the past decade K Naidoo, R Perumal The Lancet Respiratory Medicine 11 (4), 311-313, 2023 | 15 | 2023 |
